A Phase II Study of Thalidomide and Cyclophosphamide in Patients With Recurrent or Refractory Malignancies
OBJECTIVES: I. Determine the efficacy and toxic effects of thalidomide and cyclophosphamide
in patients with recurrent or refractory pediatric malignancies.
OUTLINE: Patients receive oral thalidomide 4 times daily. Cyclophosphamide is administered
IV over 1 hour once every 4 weeks, beginning on the same day as thalidomide. Treatment
continues in the absence of unacceptable toxicity or disease progression. Tumor response is
assessed every 3 months.
PROJECTED ACCRUAL: A total of 45-80 patients will be accrued for this study within 2 years.
Interventional
Primary Purpose: Treatment
Ira Dunkel, MD
Study Chair
Memorial Sloan-Kettering Cancer Center
United States: Federal Government
98-088
NCT00003754
September 1998
July 2001
Name | Location |
---|---|
Memorial Sloan-Kettering Cancer Center | New York, New York 10021 |